- Home
- VSECU vs ATAI Comparison
VSECU vs ATAI Comparison
Compare VSECU & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VSECU | ATAI |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | VSECU | ATAI |
|---|---|---|
| Price | $47.80 | $4.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 25.3K | ★ 4.2M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $38.45 | $2.00 |
| 52 Week High | $65.93 | $6.73 |
Technical Indicators
Market Signals| Indicator | VSECU | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 68.94 |
| Support Level | $44.42 | $3.46 |
| Resistance Level | $58.80 | $5.43 |
| Average True Range (ATR) | 3.18 | 0.25 |
| MACD | 0.30 | 0.06 |
| Stochastic Oscillator | 26.36 | 90.57 |
Price Performance
Historical ComparisonAbout VSECU VSE Corporation Tangible Equity Units
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.